Please use this identifier to cite or link to this item:
Type: Artigo
Title: IRS2 silencing increases apoptosis and potentiates the effects of ruxolitinib in jak2v617f-positive myeloproliferative neoplasms
Author: Campos, P.M.
Machado, J.A.N.
Eide, C.A.
Savage, S.L.
Ribeiro, R.S.
Duarte, A.S.S.
Favaro, P.
Metze, I.L.
Costa, F.F.
Tognon, C.E.
Druker, B.J.
Saad, S.T.O.
Traina, F.
Abstract: The recurrent V617F mutation in JAK2 (JAK2V617F) has emerged as the primary contributor to the pathogenesis of myeloproliferative neoplasms (MPN). However, the lack of complete response in most patients treated with the JAK1/2 inhibitor, ruxolitinib, indi
Subject: Apoptose
Country: Estados Unidos
Editor: Impact Journals
Citation: Oncotarget. Impact Journals Llc, v. 7, p. 6948 - 6959, 2016.
Rights: fechado
Identifier DOI: 10.18632/oncotarget.6851
Date Issue: 2016
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
File SizeFormat 
000376123100042.pdf4.26 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.